284 related articles for article (PubMed ID: 18521496)
1. Differences in the safety profiles of two low-molecular-weight heparins.
Ofosu FA
Thromb Haemost; 2008 Jun; 99(6):989-90. PubMed ID: 18521496
[No Abstract] [Full Text] [Related]
2. Bleeding complications after systematic switch of routine thromboprophylaxis for major orthopaedic surgery.
Kistler U; Kramers-de Quervain I; Munzinger U; Kucher N
Thromb Haemost; 2008 Jun; 99(6):1049-52. PubMed ID: 18521507
[TBL] [Abstract][Full Text] [Related]
3. Anticoagulants for thrombosis prophylaxis following surgery: a continuing saga.
Caprini JA
Thromb Haemost; 2008 Jun; 99(6):993-4. PubMed ID: 18521498
[No Abstract] [Full Text] [Related]
4. Improve the results of phase II trials of thromboprophylaxis with the new oral anticoagulant drugs.
Zufferey PJ; Samama CM; Rosencher N
Thromb Haemost; 2010 Dec; 104(6):1083-4. PubMed ID: 20886198
[No Abstract] [Full Text] [Related]
5. Safety of low-dose subcutaneous enoxaparin for the prevention of venous thromboembolism after primary intracerebral haemorrhage.
Tetri S; Hakala J; Juvela S; Saloheimo P; Pyhtinen J; Rusanen H; Savolainen ER; Hillbom M
Thromb Res; 2008; 123(2):206-12. PubMed ID: 18420258
[TBL] [Abstract][Full Text] [Related]
6. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of extended thrombo-prophylaxis in major abdominal surgery: what does the evidence show? A meta-analysis.
Bottaro FJ; Elizondo MC; Doti C; Bruetman JE; Perez Moreno PD; Bullorsky EO; Ceresetto JM
Thromb Haemost; 2008 Jun; 99(6):1104-11. PubMed ID: 18521515
[TBL] [Abstract][Full Text] [Related]
8. Extended-duration venous thromboembolism prophylaxis for medical patients.
Carson MP; Kuo YH
Ann Intern Med; 2010 Nov; 153(10):689; author reply 689-90. PubMed ID: 21079233
[No Abstract] [Full Text] [Related]
9. Extended-duration venous thromboembolism prophylaxis for medical patients.
Dentali F; Gianni M; Squizzato A
Ann Intern Med; 2010 Nov; 153(10):688; author reply 689-90. PubMed ID: 21079232
[No Abstract] [Full Text] [Related]
10. VTE primary prevention, including hospitalised medical and orthopaedic surgical patients.
Granziera S; Cohen AT
Thromb Haemost; 2015 Jun; 113(6):1216-23. PubMed ID: 25809340
[TBL] [Abstract][Full Text] [Related]
11. [Perioperative Bridging with Enoxaparin. Results of the Prospective BRAVE Registry with 779 Patients].
Omran H; Hammerstingl C; Paar WD;
Med Klin (Munich); 2007 Oct; 102(10):809-15. PubMed ID: 17928964
[TBL] [Abstract][Full Text] [Related]
12. Summaries for patients. Do the benefits of prolonged low-molecular-weight heparin treatment outweigh the harms in hospitalized patients who are bedbound?
Ann Intern Med; 2010 Jul; 153(1):I-50. PubMed ID: 20621897
[No Abstract] [Full Text] [Related]
13. Invited commentary.
Henke PK
J Vasc Surg; 2010 Nov; 52(5):1270-1. PubMed ID: 21050988
[No Abstract] [Full Text] [Related]
14. [Ambulatory therapy of thrombosis with low molecular weight heparin. Further simplification by one-time administration].
MMW Fortschr Med; 2001 Mar; 143(13):52-3. PubMed ID: 11332024
[No Abstract] [Full Text] [Related]
15. Therapeutic index of anticoagulants for prevention of venous thromboembolism following orthopedic surgery: a dose-response meta-analysis.
Mandema JW; Boyd RA; DiCarlo LA
Clin Pharmacol Ther; 2011 Dec; 90(6):820-7. PubMed ID: 22048231
[TBL] [Abstract][Full Text] [Related]
16. The problem of risk assessment and prophylaxis of venous thromboembolism in pregnancy.
Krafft A
Thromb Haemost; 2007 Dec; 98(6):1155-6. PubMed ID: 18064306
[No Abstract] [Full Text] [Related]
17. Deep-vein thrombosis in malignancy: how long should patients be treated, and with what?
Merli GJ
Catheter Cardiovasc Interv; 2009 Jul; 74 Suppl 1():S27-34. PubMed ID: 19530157
[TBL] [Abstract][Full Text] [Related]
18. How useful is determination of anti-factor Xa activity to guide bridging therapy with enoxaparin? A pilot study.
Hammerstingl C; Omran H; Tripp C; Poetzsch B
Thromb Haemost; 2009 Feb; 101(2):325-32. PubMed ID: 19190817
[TBL] [Abstract][Full Text] [Related]
19. Interpretation of benefit-risk of enoxaparin as comparator in the RECORD program: rivaroxaban oral tablets (10 milligrams) for use in prophylaxis in deep vein thrombosis and pulmonary embolism in patients undergoing hip or knee replacement surgery.
Van Thiel D; Kalodiki E; Wahi R; Litinas E; Haque W; Rao G
Clin Appl Thromb Hemost; 2009; 15(4):389-94. PubMed ID: 19608550
[TBL] [Abstract][Full Text] [Related]
20. Peripheral nerve block catheters and low molecular weight heparin.
Ben-David B; Chelly JE
Anesth Analg; 2007 Apr; 104(4):990-1; author reply 991-2. PubMed ID: 17377121
[No Abstract] [Full Text] [Related]
[Next] [New Search]
